RxDx: Achieving the End Goal for Personalized Medicine
By Catherine Hollingsworth
Monday, February 9, 2009
Ten years ago, Genentech's Herceptin stood alone as the first drug required to be paired with a genetic test to determine which patients are likely respond to the cancer therapy. Now, a new crop of so-called companion diagnostics are emerging - including KRAS and EGF mutation tests, for example - that would serve a similar purpose to the HER2 test kits.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.